Freemont Management’s AbbVie ABBV Stock Holding History

Freemont Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,200	Closed	-$2.22M	–	17
2026 Q1	$2.22M	Sell	10,200 -1,100	-10%	-$244K	0.34%	84
2025 Q4	$2.58M	Buy	11,300 +10,300	+1,030%	+$2.35M	0.45%	62
2025 Q3	$232K	Sell	1,000 -7,600	-88%	-$1.55M	0.12%	95
2025 Q2	$1.6M	Buy	8,600 +2,000	+30%	+$372K	0.24%	82
2025 Q1	$1.38M	Sell	6,600 -600	-8%	-$117K	0.45%	71
2024 Q4	$1.28M	Hold	7,200	–	–	0.56%	62
2024 Q3	$1.42M	Hold	7,200	–	–	0.7%	49
2024 Q2	$1.23M	Sell	7,200 -35,800	-83%	-$5.93M	0.58%	43
2024 Q1	$7.83M	Sell	43,000 -13,300	-24%	-$2.29M	1.12%	31
2023 Q4	$8.72M	Hold	56,300	–	–	1.1%	31
2023 Q3	$8.39M	Sell	56,300 -9,500	-14%	-$1.39M	1.25%	27
2023 Q2	$8.87M	Hold	65,800	–	–	1.07%	32
2023 Q1	$10.5M	Hold	65,800	–	–	1.47%	22
2022 Q4	$10.6M	Hold	65,800	–	–	1.67%	20
2022 Q3	$8.83M	Sell	65,800 -1,600	-2%	-$230K	1.61%	17
2022 Q2	$10.3M	Sell	67,400 -3,400	-5%	-$520K	1.78%	17
2022 Q1	$11.5M	Buy	+70,800	New	+$10.3M	1.73%	13
2021 Q4	–	Sell	-102,300	Closed	-$11M	–	66
2021 Q3	$11M	Buy	102,300 +400	+0.4%	+$45.7K	1.46%	22
2021 Q2	$11.5M	Hold	101,900	–	–	1.65%	16
2021 Q1	$11M	Hold	101,900	–	–	1.8%	17
2020 Q4	$10.9M	Buy	+101,900	New	+$9.79M	2.03%	15

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Freemont Management's ABBV Position: Q2 2026 in Review

Freemont Management sold out of AbbVie (ABBV) in Q2 2026, closing a stake of 10,200 shares — an estimated $2.22M sold.

Freemont Management first reported a position in ABBV in Q4 2020 and held it in 21 quarters. The position peaked at $11.5M in Q2 2021. 4,207 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Freemont Management reported no remaining AbbVie position as of Q2 2026 after selling out during the quarter.
Freemont Management sold 10,200 AbbVie shares in Q2 2026, an estimated $2.22M.
Freemont Management first reported a position in AbbVie in Q4 2020 and held it in 21 quarters.
Freemont Management's AbbVie position peaked at $11.5M in Q2 2021.
4,207 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Freemont Management's 13F filing for Q2 2026, filed 11 Aug 2026.